L3VLUP
ProSign in

TECH · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TECHGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TECH
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterTECHGILD
Q3 202014 holders, $1.2bn25 holders, $14.2bn
Q4 202010 holders, $1.2bn27 holders, $13.4bn
Q1 202111 holders, $1.5bn24 holders, $14.5bn
Q2 20216 holders, $1.4bn18 holders, $14.9bn
Q3 20218 holders, $1.5bn20 holders, $16.4bn
Q4 20219 holders, $1.9bn20 holders, $16.8bn
Q1 20227 holders, $1.3bn28 holders, $13.2bn
Q2 202213 holders, $1.3bn26 holders, $13.6bn
Q3 202213 holders, $1.0bn24 holders, $13.3bn
Q4 20229 holders, $954m32 holders, $21.1bn
Q1 202315 holders, $896m27 holders, $21.8bn
Q2 202310 holders, $1.2bn24 holders, $20.7bn
Q3 202310 holders, $960m24 holders, $20.0bn
Q4 202310 holders, $1.2bn22 holders, $21.5bn
Q1 20248 holders, $1.2bn30 holders, $20.3bn
Q2 20247 holders, $1.4bn28 holders, $18.5bn
Q3 202410 holders, $2.1bn29 holders, $24.2bn
Q4 20248 holders, $1.7bn28 holders, $25.9bn
Q1 20258 holders, $1.2bn33 holders, $32.0bn
Q2 20258 holders, $860m27 holders, $30.9bn
Q3 202514 holders, $1.4bn23 holders, $29.4bn
Q4 202513 holders, $1.7bn25 holders, $34.3bn
Q1 202610 holders, $1.6bn25 holders, $38.5bn
Q2 202621 holders, $2.6bn26 holders, $34.2bn
TECH

Bio-techne Corp

Holders
8
Reported value
$1.7bn
Buyers
4
Sellers
4

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
28
Reported value
$25.9bn
Buyers
14
Sellers
14

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2024

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TECH (4)

Freestone Grove Partners LP, MFS Investment Management, Neuberger Berman Group LLC, Polen Capital Management LLC

Only GILD (24)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Man Group PLC, PDT Partners LLC, Point72 Asset Management LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →